Challenges to determining whether DHA can protect against age-related cognitive decline

Q Medicine

Clinical Lipidology Pub Date : 2015-02-01 DOI:10.2217/clp.14.61

Marie Hennebelle, E. Harbeby, S. Tremblay, R. Chouinard‐Watkins, F. Pifferi, M. Plourde, P. Guesnet, S. Cunnane

引用次数: 11

Abstract

Abstract DHA, an omega-3 fatty acid, is an important constituent of brain membranes and has a key role in brain development and function. This review aims to highlight recent research on DHA’s role during age-related cognitive decline and Alzheimer’s disease. Animal and in vitro studies have provided some interesting mechanistic leads, especially on brain glucose metabolism, that may be involved in neuroprotection by DHA. However, results from human studies are more mitigated, perhaps due to changing DHA metabolism during aging. Recent innovative tools such as 13C-DHA for metabolic studies and 11C-DHA for PET provide interesting opportunities to study factors that affect DHA homeostasis during aging and to better understand whether and how to use DHA to delay or treat Alzheimer’s disease.

查看原文本刊更多论文

确定DHA是否可以防止与年龄相关的认知能力下降的挑战

DHA是一种omega-3脂肪酸，是脑膜的重要成分，在大脑发育和功能中起着关键作用。本文综述了DHA在年龄相关认知能力下降和阿尔茨海默病中的作用。动物和体外研究提供了一些有趣的机制线索，特别是在脑葡萄糖代谢方面，这可能涉及DHA的神经保护作用。然而，人类研究的结果则更为缓和，可能是由于衰老过程中DHA代谢的变化。最近的创新工具，如用于代谢研究的13C-DHA和用于PET的11C-DHA，为研究衰老过程中影响DHA稳态的因素以及更好地了解是否以及如何使用DHA延缓或治疗阿尔茨海默病提供了有趣的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.